Using Algorithm Guided Programming to Treat Parkinson’s Disease Patients Implanted with Deep Brain Stimulation
Objective: To compare acute outcomes from Parkinson’s disease patients implanted with Deep Brain Stimulation (DBS) programmed using Algorithm Guided Programming (AGP) versus conventional, standard of…Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage
Objective: To assess the differences between two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: Opicapone and ENT are COMT inhibitors developed as adjunct…Combining Carbidopa/levodopa Extended-release Capsules and Immediate-release Tablets – Crucial Factors of This Economical Prescription
Objective: We introduced a new way of prescribing carbidopa/levodopa extended-release (ER) capsule – combining use of immediate-release (IR) tablets. This retrospective clinical study was designed…Recruitment of Ethnoracially Diverse Participants for Disease-Modifying Drug Trials in Parkinson’s Disease: Are We Doing It Right? A Systematic Review and Meta-Analysis.
Objective: To perform a systematic review and meta-analysis on recruitment of people with Parkinson’s disease (PwP, PD) from different ethnic and racial groups in disease-modifying…Prediction of The Monopolar Review in Deep Brain Stimulation for Parkinson’s Disease using Imaging
Objective: To build an AI model that can predict the monopolar review in deep brain stimulation (DBS) for Parkinson’s disease (PD) based on imaging. Background:…Indications of advanced therapies in Parkinson’s Disease: a retrospective study in a Belgian reference center
Objective: The aim of our study is to assess whether our patients with Parkinson’s disease (PD) met recommended criteria to perform advanced therapy (AT) like…Efficacy and Safety of Amantadine in Parkinson’s Disease with Dyskinesia and Motor Fluctuations: A Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of oral amantadine (AMA) compared to placebo in the treatment of dyskinesia (DYS) and motor fluctuations (MF) in…Adherence and Persistence Among Patients with Parkinson’s Disease Initiating Istradefylline: 12-Month Follow-Up from US Real-World Data
Objective: To evaluate 12-month adherence and persistence and identify factors associated with persistence among Parkinson’s disease (PD) patients initiating istradefylline, the first non-dopaminergic adjunct targeting…TrkB modulator OT-003 reduces dopaminergic cell loss, mitochondrial stress, alpha-synuclein aggregation and motor dysfunction in Parkinson’s disease models.
Objective: To assess efficacy and potency of our proprietary lead compound OT-003, an orally bioavailable small molecule Tropomyosin receptor kinase B (TrkB) modulator, in preclinical…Boosting Clinical Trial Power in Parkinson’s Disease with AI-Generated Digital Twins
Objective: To evaluate the incorporation of prognostic digital twins to enhance traditional clinical trials in Parkinson’s Disease (PD) for disease modifying therapies. We assess the…
- « Previous Page
- 1
- …
- 415
- 416
- 417
- 418
- 419
- …
- 1942
- Next Page »